|
KMID : 0941820220320030215
|
|
Korean Journal of Clinical Pharmacy
2022 Volume.32 No. 3 p.215 ~ p.225
|
|
|
Cost Avoidance and Clinical Pharmacist Interventions on Hospitalized Patients in Hematologic malignancies
|
|
Kim Ye-Seul
Hong So-Yeon
Kim Yoon-Hee
Choi Kyung-Suk
Lee Jeong-Hwa
Lee Ju-Yeun
Lee Euni
|
|
|
Abstract
|
|
|
Background: Patients with hematologic cancers have a risk of drug-related problems (DRPs) from medications associated withchemotherapy and supportive care. Although the role of oncology pharmacists has been widely documented in the literature, fewstudies have reported its impact on cost reduction. This study aimed to describe the activities of oncology pharmacists with respect tohematologic diseases and evaluate the associated cost avoidance.
Methods: From January to July 2021, patients admitted to thedepartment of hemato-oncology at Seoul National University, Bundang Hospital were studied. The activities of oncologypharmacists were reported by DRP type following the Pharmaceutical Care Network version 9.1 guidelines, and the acceptance ratewas calculated. The avoided cost was estimated based on the cost of the pharmacy intervention, pharmacist manpower, andprescriptions associated with the intervention.
Results: Pharmacists intervened in 584 prescriptions from 208 patients during thestudy period. The most prevalent DRP was “adverse drug event (possibly) occurring” (32.4%), followed by “effect of drug treatmentnot optimal” (28.6%). “Drug selection” (42.5%) and “dose selection” (30.3%) were the most common causes of DRPs. Theacceptance rate of the interventions was 97.1%. The total avoidance cost was KRW 149,468,321; the net profit of the avoidance cost,excluding labor costs, was KRW 121,051,690; and the estimated cost saving was KRW 37,223,748.
Conclusion: Oncologypharmacists identified and resolved various types of DRPs from prescriptions for patients with hematologic disease, by reviewingthe prescriptions. Their clinical service contributed to enhanced patient safety and the avoidance of associated costs.
|
|
|
KEYWORD
|
|
|
Clinical pharmacist, inappropriate prescribing, pharmacy service, hospital economics
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|